Tarsus director plans $980K stock sale in 2026

Tarsus Pharmaceuticals, Inc. (TARS) received a notice under Rule 144 that director J. Link plans to sell 12,500 shares of common stock through Merrill Lynch on or about September 15, 2026 on Nasdaq.

Available on EDGAR 09/15/2026 - 04:52 PM EDT Accepted by SEC EDGAR 09/15/2026 - 04:51 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) received a notice under Rule 144 that director J. Link plans to sell 12,500 shares of common stock through Merrill Lynch on or about September 15, 2026 on Nasdaq. The shares were acquired on January 10, 2017 via a stock option exercise paid in cash.

Key Figures

Shares proposed to be sold: 12,500 shares Aggregate market value of proposed sale: $979,745.36 Shares outstanding: 43,882,996 shares +2 more

5 metrics

Shares proposed to be sold 12,500 shares Planned sale of Tarsus Pharmaceuticals common stock under Rule 144

Aggregate market value of proposed sale $979,745.36 Value for 12,500 shares of common stock in the Rule 144 notice

Shares outstanding 43,882,996 shares Common stock outstanding for Tarsus Pharmaceuticals as referenced in the notice

Approximate sale date September 15, 2026 Planned date of sale on Nasdaq

Acquisition date of shares January 10, 2017 Date the shares were acquired via stock option exercise

Key Terms

Rule 144, stock option exercise, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"COMMON | 01/10/2017 | STOCK OPTION EXERCISE | TARSUS PHARMACEUTICALS INC"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"COMMON | MERRILL LYNCH ... | 12500 | 979745.36 | 43882996"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Tarsus Pharmaceuticals (TARS)?

It reports that director J. Link plans to sell 12,500 shares of Tarsus Pharmaceuticals common stock under Rule 144, indicating a proposed resale of restricted or control securities through a broker on Nasdaq.

How many TARS shares are proposed to be sold in this Form 144?

The filing states a proposed sale of 12,500 shares of Tarsus Pharmaceuticals common stock, to be executed through Merrill Lynch on or about September 15, 2026.

When and how were the TARS shares being sold acquired?

The shares were acquired on January 10, 2017 through a stock option exercise, with the consideration described as cash.

What is the aggregate market value of the TARS shares in this planned sale?

The Form 144 lists an aggregate market value of $979,745.36 for the 12,500 shares of Tarsus Pharmaceuticals common stock proposed to be sold.

How many TARS shares are outstanding according to this Form 144?

The notice reports 43,882,996 shares of Tarsus Pharmaceuticals common stock outstanding, providing context for the relative size of the 12,500-share proposed sale.

On which exchange will the TARS shares be sold under this Form 144?

The Form 144 indicates that the 12,500 shares of Tarsus Pharmaceuticals common stock are expected to be sold on the Nasdaq market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001228684
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TARSUS PHARMACEUTICALS INC
SEC File Number	001-39614
Address of Issuer	17700 LAGUNA CANYON ROAD FLOOR4 IRVINE CALIFORNIA 92618
Phone	949-418-1801
Name of Person for Whose Account the Securities are To Be Sold	WILLIAM J LINK
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	DIRECTOR

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 520 NEWPORT CENTER DRIVE 20TH FLOOR NEWPORT BEACH CA 92660	12500	979745.36	43882996	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/10/2017	STOCK OPTION EXERCISE	TARSUS PHARMACEUTICALS INC			12500	01/10/2017	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	WILLIAM J LINK
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)